Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K on May 24, 2017, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a contractual amendment.
Material Changes
On May 24, 2017, the Company amended its patent license agreement with the Regents of the University of Michigan (originally dated December 22, 2014). The material changes include:
- Modification of the Company's milestone payment obligations under the agreement.
- Reduction of the aggregate research sponsorship amount over a three-year period from $2,715,000 to $2,100,000.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The full text of the Amendment, with confidential terms redacted, is scheduled to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the period ending June 30, 2017.
Investor Verification Points
- Verify the specific details of the modified milestone payment obligations in the upcoming Form 10-Q exhibit.
- Confirm the impact of the $615,000 reduction in research sponsorship on the Company's cash burn rate and future funding requirements.
- Review the full text of the Amendment to understand any other terms not summarized in this 8-K.